Clinical trial · Observational
Metabiomics Colon Cancer Clinical Research Study
NCT02151123CI-TRIAL-00095866withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): funding not secured
Summary
Brief summary (as posted)
The specific aim of the study is to determine the false negative rate of the Metabiomics Colon Polyp and Colorectal Cancer Assay for Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Diagnosed colon cancer patients
- description
- Patients undergoing colectomy for colonic adenocarcinoma.
Primary outcomes (1)
- measure
- False negative rate of test for colon cancer
- timeFrame
- immediately post surgery
- description
- The False Negative Rate is calculated as (100\*False Negative) /(True Positive + False Negative).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * Recently diagnosed with colorectal cancer (CRC) and scheduled for colectomy * Male or female, * Age: 18-95 years, * Able to comprehend, sign, and date the written informed consent form (ICF), * Able to give informed consent in English * Women and minorities will be included. Exclusion Criteria: * History of Inflammatory Bowel Disease * Antibiotics within 2 weeks of sample collection. * Colonoscopy, colon prep or bowel contrast agent within 7 days prior to sample collection * Any radiation therapy
References
Publications (0)
Data not yet available
No reference posted for this study.